Compare MSEX & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSEX | SANA |
|---|---|---|
| Founded | 1897 | 2018 |
| Country | United States | United States |
| Employees | 395 | N/A |
| Industry | Water Supply | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.5M | 793.1M |
| IPO Year | N/A | 2021 |
| Metric | MSEX | SANA |
|---|---|---|
| Price | $57.66 | $3.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $61.33 | $7.80 |
| AVG Volume (30 Days) | 153.9K | ★ 3.8M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.60 | N/A |
| Revenue Next Year | $10.94 | N/A |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.94 | $2.61 |
| 52 Week High | $62.18 | $6.55 |
| Indicator | MSEX | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 73.53 | 74.10 |
| Support Level | $49.91 | $3.62 |
| Resistance Level | $62.18 | $4.08 |
| Average True Range (ATR) | 1.20 | 0.22 |
| MACD | 0.47 | 0.09 |
| Stochastic Oscillator | 93.28 | 98.41 |
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.